Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Verification through Accelerated testing Leading to Improved wave energy Designs (VALID)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Low-cost, low-carbon energy supply
Action type: Research and Innovation actions
Countries involved: Austria,Spain,Italy,Italy,Spain,Spain,Ireland,Sweden,Sweden,Netherlands,Denmark,Denmark,Portugal,Denmark,Denmark
Call: New test rig devices for accelerating ocean energy technology development (H2020-LC-SC3-2020-RES-RIA, 2020)
Start date: 2020-12-01
End date: 2024-05-31
Duration (months): 42.0
Total project cost (EUR): 4993651.25
EU funding (EUR): 4993651.25
Participants: 16
Project status: SIGNED

The VALID project will develop and validate a new test rig platform and procedures for accelerated hybrid testing that can be used across the wave energy sector to improve the reliability and survivability of the components and subsystems that form Wave Energy Converters (WECs). The methodology for accelerated hybrid testing combines both physical testing (physical test rigs) and virtual testing (simulated environment, numerical models and data). The VALID Hybrid Test Platform (VHTP) will become the interface that allows for seamless accelerated hybrid testing. With the long-term goal of establishing a standard for future use and making a step-change impact on the sector, the new test rig platform and methodology will be validated for a variety of WECs, critical components and subsystems through three different user cases. Often faults in component and subsystems are detected through extensive and costly sea testing in late stages of device development (high TRLs) and finding a problem at late development stages can add significant cost and delays to initial schedules, eventually leading to company’s bankruptcy. Sound testing methods are thus needed to reduce the uncertainties, increase confidence in results, assist and guide the concept and subcomponents design, and thus largely assist in the decision-making progress. The new hybrid testing platform with open access for models, testbeds and improved data management are all necessary to lower the cost on future technologies. VALID assembles the full value chain required from methodology and platform development (AVL, Aquatera), technology development (Corpower, IDOM, Wavepiston), LCOE (Julia F Chosaz Consult Engineering) to certification bodies (RINA-C) in order to develop an integrated solution with support from RTO (RISE, Tecnalia, Bimep) and academia (Aalborg University, TUDelft).

Keywords: hybrid testing,accelerated testing,new testing procedures,test rigs,components,subsystems,lcoe,performance,prolonged lifetime,reduced maintenance,survivability,reliability,models,virtual
Quantum computing with atom arrays—bringing Europe to the forefront of the quantum race (FRESNEL)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2021-04-01
End date: 2023-03-31
Duration (months): 24.0
Total project cost (EUR): 3564375.0
EU funding (EUR): 2495062.5
Participants: 1
Project status: CLOSED

Pasqal is a spin-out from Institut d’Optique in Palaiseau, one of the leading quantum research centres in the world. We have developed the first large-scale neutral atom quantum processing units (QPUs). Our current prototype contains 100-qubits making it one of the most powerful QPUs ever developed. Our next objective is to develop and industrialise the 300-qubits QPU series—Fresnel300. These QPUs will provide enterprise users with unprecedented simulation and optimisation capabilities. This ambitious project relies on Pasqal’s unique technical capabilities. Our scientific founders have pioneered techniques for the precise manipulation of neutral atoms with lasers. Neutral atoms are the most promising approaches for building commercial-grade quantum computers. Unlike other quantum computing technologies, neutral atom platforms are intrinsically scalable. Atoms do not suffer from manufacturing irregularities and do not require expensive and bulky dilution refrigerators. From 2023, we will be able to provide 100-qubit QPUs to high-performance computing (HPC) centres as computational accelerators. Two leading European HPC centres—Très Grand Centre de Calcul du CEA (France) and Jülich Supercomputing Centre (Germany)—have already expressed their interest in purchasing Pasqal’s QPUs. The Fresnel300 QPUs will be ready by 2024 and available for use via Pasqal’s cloud platform. Enterprises will be able to leverage quantum capabilities to solve complex computational problems using our service. Leading enterprises like Électricité de France and Total SE have already shown interest in using our technology to solve challenging optimisation problems.

Keywords: quantum computing,quantum advantage,simulation technology,lasers,atomic physics
Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics (3D NEONET)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Spain,Spain,Ireland,Ireland,Ireland,Germany,Spain,Spain,Spain,Sweden,United States,United Kingdom,Portugal,United Kingdom
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2016, 2016)
Start date: 2017-01-01
End date: 2022-06-30
Duration (months): 66.0
Total project cost (EUR): 945000.0
EU funding (EUR): 945000.0
Participants: 23
Project status: CLOSED

Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascular permeability) play also pivotal roles in cancer, being therapeutic targets to treat both kind of diseases. The overall goal of 3D-NEONET is the improvement of available treatments for cancer and ocular disease by enhancing drug discovery-development and delivery to targeted tissues, through advanced international co-operation between academic and non-academic partners. The interdisciplinary expertise provided by 18 partners in 7 countries encompasses among others: drug screens, ADME, toxicology, preclinical models, nanotechnology, biomaterials and clinical trials. After the success with ongoing FP7-IAPP project 3D-NET (Drug Discovery and Development of Novel Eye Therapeutics; (www.ucd.ie/3dnet), we are assembling 3D-NEONET, this enlarged European interdisciplinary consortium that will join forces and exchange skills to enhance current therapies in oncology and ophthalmology. The 3 global objectives of 3D-NEONET are: 1- Enhance the discovery and development of novel drugs, targets and biomarkers for ophthalmology and oncology. 2- Improve the Delivery of Therapeutics for Oncology and Ophthalmology 3- Enhancement of Research, Commercial and Clinical Trial Project Management Practices in these fields. Through participation in the program, 3D-NEONET is the vehicle for driving synergies between academic and non-academic participants leading to increased scientific and technological excellence as well as tangible innovative outputs that will strengthen the competitiveness of both the researchers and industries of the network even beyond the lifetime of the network.

Keywords: zebrafish,phenotype based drug discovery,drug delivery,natural products,drug metabolism,cancer xenografts,colorectal,oesophageal cancer,uveal melanoma,diabetic retinopathy,amd clinical trials
New stability testing method to predict the performance of amorphous formulations (AMORPHORM)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Denmark
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Duration (months): 24.0
Total project cost (EUR): 212194.8
EU funding (EUR): 212194.8
Participants: 1
Project status: TERMINATED

The importance of amorphous water-soluble substances has been increasingly recognized over last two decades in the pharmaceutical and food industries. Amorphous solids of small molecules offer a solubility advantage over their crystalline counterparts. Parallel to that, large molecular systems, such as proteins and enzymes, are difficult to crystallize but are often stabilized in amorphous formulations. Amorphous systems are inherently unstable and hence more prone to physico-chemical changes. In order to increase the safety and reduce the risk of their usage for both human patients/customers and industry it is necessary to determine their long-term physico-chemical stability. There is currently no existing reliable and widely applicable method for stability testing of amorphous formulations. During my research I have demonstrated such a method can be based on a terahertz spectroscopy, which probes the mobility of molecules when they are solids. I found that this approach is universal and should be able to be applied for all hydrogen bonding solids, which spans almost all organic compounds. The objectives of the proposal can be split into 3 blocks. The technology block will focus on developing terahertz spectroscopy into a reliable stability testing method to industrial standards and to explore whether more affordable instrumentation can be deployed alternatively to reduce the capital cost of the method. In the pharmaceutical block we will aim to determine how pharmaceutical formulation and processing steps can be optimised for amorphous stability. We will examine also critical storage conditions for the amorphous products and how to prevent any recrystallization during their dissolution. In the food and biotechnology block we will aim to transfer the methods developed for small drug molecules to protein and enzyme preservation in glassy matrices.

Keywords: amorphous,glass,supercooled,stability,crystallisation,molecular mobility,solubility,formulation,pharmaceutical,spectroscopy,thermal analysis
4D analysis of heart development and regeneration using advanced light microscopy (4DHeart)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Industrial Doctorates
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain,Germany,Spain,Germany,Switzerland,Belgium,Switzerland,France,France,France
Call: Innovative Training Networks (H2020-MSCA-ITN-2016, 2016)
Start date: 2017-01-01
End date: 2021-02-28
Duration (months): 50.0
Total project cost (EUR): 1487736.62
EU funding (EUR): 1487736.6199999999
Participants: 15
Project status: CLOSED

Cardiovascular (CV) disease is a main cause of death worldwide. During adulthood, ischemic heart disease leads to heart failure and perinatally, congenital heart defects are found in over 20% of deaths. Moreover, genetic or epigenetic factors altering development can have an impact much later in life. These facts underscore the need of a better understanding of the genetic and environmental factors that influence CV development. An important way to increase our knowledge is by visualizing cardiac development in vivo. Recent advance in microscopy allows monitoring CV development at a cellular level in organisms such as the zebrafish model. Particularly revolutionary has been the development of light sheet microscopy (LSM). We want to further exploit LSM for in vivo manipulation of cells in the embryonic zebrafish heart and measure with high precision biophysical parameters, by introducing novel features to LSM such as optical tweezers. High throughput cardiac imaging protocols for zebrafish larvae suitable for screenings will be set up. We will develop softwares to enhance resolution of acquisition, large dataset handling and image-processing. The aim is to generate a toolbox to be implemented into existing software packages allowing a complete modeling of zebrafish cardiac morphogenesis. We will adapt LSM for adult zebrafish hearts to study cardiac regeneration and mouse heart development at cellular resolution. Each Early Stage Researchers (ESRs) will develop their own technology to solve a biological problem at the frontier of knowledge. ESRs will receive multidisciplinary (CV development, physics, biocomputing, bioimaging) as well as intersectorial (academic research, SMEs, large companies) training and will achieve unique skills on microscopy, in-vivo imaging and image analysis allowing them to interrogate questions on cardiac development and regeneration. Their profile will be at the interface of a bioengineer and a life science researcher filling a currently existing gap on the market.

Keywords: in vivo imaging,image processing,cardiac development,zebrafish,mouse,light sheet,microscopy,optical tweezers,high through put screening,epicardium,valves,flow forces
Wireless Brain-Connect inteRfAce TO machineS: B-CRATOS (B-CRATOS)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Italy,Germany,Italy,Germany,Norway,Sweden,France,United States
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2020)
Start date: 2021-03-01
End date: 2025-02-28
Duration (months): 48.0
Total project cost (EUR): 4653611.25
EU funding (EUR): 4475059.25
Participants: 8
Project status: SIGNED

Wireless Brain-Connect inteRfAce TO machineS: B-CRATOS:Merging novel wireless communication, neuroscience, bionics, Artificial Intelligence and sensing to create for the first time a battery-free high-speed wireless in-body communication platform for Brain-Machine-Body connectivity. Groundbreaking technological components - wireless two-way microwave fat intra-body and RF backscatter communication, battery-free powering technology, bio-inspired sensing, dexterous biomechatronic extremity- will be codesigned and a proof-of-concept, revolutionary untethered brain-machine interface will be created. This technology will have profound impact in the fields of neuroprosthetics (restoration of missing biological functions such as vision, audition, movement, sensation, movement, cognition through the bypassing damaged circuits), Brain-Computer Interfaces (brain plasticity through machine learning, gaming, virtual reality), and electroceuticals (modulation of organ function through neural circuits instead of pharmaceuticals), gaming (immersion), and Virtual Reality. B-CRATOS will overcome major challenges relating to power consumption, batteries, and data transmission bandwidth through breakthrough battery-free bidirectional wireless communication technology. The revolutionary signal bridge technology will impact healthcare, quality-of-life, and human learning and cognition. Key Enabling Technologies for this closed-loop functionality include ultra-low-power ASIC brain implants with read/write capability, battery-free in-body high-speed wireless communications systems, human-like artificial sensors and limbs.

Keywords: neuroprosthetics,brain machine interface,fat ibc,electroceuticals,brain computer interface bci,medical device,neural control of movement mcm,neuromodulation
Bacteriophages, phage-host interactions and evolution of defence mechanisms in beneficial bacterium Propionibacterium freudenreichii (CO-DEfENDENCE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-01-01
End date: 2023-11-09
Duration (months): 24.0
Total project cost (EUR): 219312.0
EU funding (EUR): 219312.0
Participants: 1
Project status: SIGNED

Bacteriophages (phages) infecting Propionibacterium freudenreichii, a bacterium known for production of active vitamin B12 and for causing well-documented benefits to human health, are more diverse than those identified for closely related genera. At the same time, the defence mechanisms protecting the bacterial strains (hosts) from phage attacks are more diverse as well. These two phenomena suggest that P. freudenreichii strains and their phages have experienced complex interactions in phage-bacterium arms race. However, both phages attacking, and the defence mechanisms that this important food-grade Actinobacterium uses to protect itself from phage attacks are currently severely understudied. In CO-DEfENDENCE, I will use an innovative approach of systematic study of the defence mechanisms not only from the perspective of the bacterium, but also from the perspective of the phage. The use of strains and phages isolated from samples of different origin will ensure diversity of material subjected to analyses by a combination of phenotypic, genomic, proteomic and imaging methods. This multidisciplinary approach is possible due to guidance offered by world-class phage specialists at one of the world’s top universities, the University of Copenhagen. The expected result of CO-DEfENDENCE is elucidation of complex interactions between P. freudenreichii and its phages, which led to the high diversity of the phages and the multitude of defence mechanisms employed by the strains. As an added benefit, these results have a great potential for being translated into novel genetic tools and to aid the development of phage therapies, especially those aimed at pathogenic Actinobacteria.

Keywords: bacteriophage,propionibacterium,page host interactions,probiotics
InnovaTIve care services, enhanced with technology, to deliver QUick rEsponses for individuals with advanced heart failure and complex care needs through integrated care (TIQUE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Health care provision and integrated care
Action type: Pre-Commercial Procurement
Countries involved: Spain,Israel,Italy,Spain,Sweden,United Kingdom
Call: Pre-commercial procurement (PCP) for integrated care solutions (H2020-SC1-2020-Single-Stage-RTD, 2020)
Start date: 2021-03-01
End date: 2026-02-28
Duration (months): 60.0
Total project cost (EUR): 6327249.94
EU funding (EUR): 5694524.95
Participants: 8
Project status: SIGNED

Heart failure (HF) is the leading cause of hospitalisation in people over the age of 65 and carries a high cost to healthcare systems. It also exerts a significant economic toll on patients, their families and society in general; more the 15 million people are living with HF in Europe. Despite the considerable burden to human life and healthcare costs there has been scarce innovation in treatments in the past several decades: HF occurs mainly in the older population that may mistake symptoms as being the natural result of ageing and therefore not recognized until the condition has reached a severe stage. Poor management of HF increases the risk and frequency of acute episodes resulting in hospitalizations, poor quality of life and high burden on healthcare systems. The recent COVID-19 pandemic has evidenced that fearing to be infected, cardiovascular patients delay care. A state-of-the-art search indicated that that integrated care is crucial for improving the health care services, wellbeing and engagement through shared decision-making, education and support to self-management. Existing solutions are local and there is no common effective solution available in the market. Public procurers cannot go to open tender to deploy effective solutions for advanced heart failure. The TIQUE Consortium recognised Pre-Commercial Procurement (PCP) as the only way to stimulate the market to find a solution to the common problem. TIQUE will bring to the market new integrated care solutions implementing a predictive, preventive, personalized and participatory model of health care services for patients with heart failure. TIQUE will stimulate European industry to become a global leader in this innovative field. Use of PCP is of particular interest to the consortium members some of them are familiar with PCP and PPI and in using them strategically while others are new adopters. The consortium will proactively share PCP knowledge with the PiPPI and EURIPHI communities of practice.

Keywords: integrated care,heart failure,frailty,ehealth,artificial intelligence
Supercomputing Expertise for SmAll and Medium Enterprise Network (SESAME NET)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: e-Infrastructures
Action type: Coordination and support actions
Countries involved: Spain,Ireland,Germany,Bulgaria,Lithuania,Romania,Greece,Belgium,Croatia,Poland,Croatia,Slovenia,Czechia,United Kingdom,Portugal
Call: Network of HPC Competence Centres for SMEs (H2020-EINFRA-2014-2, 2014)
Start date: 2015-06-01
End date: 2017-05-31
Duration (months): 24.0
Total project cost (EUR): 1998363.75
EU funding (EUR): 1998363.75
Participants: 17
Project status: CLOSED

Network of HPC Competence Centres for SMEs
Effective Multidrug Cocktails for Cancer (EMbRACe)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Israel
Call: ERC Proof of Concept Grant (ERC-2015-PoC, 2015)
Start date: 2016-11-01
End date: 2018-04-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Cancer is a global epidemic that affects all ages and socio-economic groups. In turn, tremendous resources are being invested in prevention, diagnosis, and treatment of cancer. For instance, over 1,000 anticancer drugs are currently in various phases of development and pre-approval testing, more than the number for heart disease, stroke, and mental illness combined. Finding multi-drug combinations for cancer is an increasingly pressing therapeutic challenge. However, screening all possible drug combinations is an impossible task because the number of experiments grows exponentially with the number of different drugs and doses. Therefore, highly effective combinations of already approved drugs may likely exist that have never been tested before at the appropriate doses, due the astronomical number of wet lab tests required to find these combinations. Motivated by this challenge, we have developed a novel method for computing the effects of high order combinations of drugs on cancer cells and predicting the best drug for a given tumor based only on a very small number of experiments. In turn, the goals of our PoC project are to further validate the potential of our formula by means of numerous rigorous tests and to establish the business potential of our idea. If successful, this PoC project will pave the way to the development and adoption of highly personalized drug cocktails that are designed based only on a limited number of measurements performed on patient-derived tumor material.

Keywords: cancer,anti cancer drugs,combination therapy,personalized drug cocktails